Search Clinical Trials in the European Union

Duration
Visits
Phase
Oral
Benefits
Drugs
Locations
Clinical Specialty
41-60 of 1,694 trials

Arrhythmic Mitral Valve Prolapse: Flecainide and Metoprolol Study

We are studying whether adding flecainide to metoprolol can better reduce irregular heartbeats in patients with arrhythmic mitral valve prolapse. This trial aims to assess the safety and effectiveness of this combination treatment.

Mitral Valve Prolapse>2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteCardiologyInternal Medicine

Atrial Fibrillation: Colchicine Study

We are investigating whether colchicine can help prevent the return of atrial fibrillation in patients scheduled for heart rhythm treatment. We will also look at its effects on heart health and quality of life.

Atrial Fibrillation and Atrial Flutter>2 yearsConfirmation phase (III)≤5 visitsStandard MedicinesCardiology

Post-Traumatic Stress Disorder: Testing New Therapy

We are studying a new therapy called reconsolidation therapy for people with severe PTSD. This trial compares it to standard treatment and looks at whether adding propranolol can improve outcomes.

Post-Traumatic Stress Disorder≤3 monthsEfficacy phase (II)No PlaceboStandard MedicinesPsychiatry

Aspirin for Preventing Preeclampsia in First-Time Pregnant Women

We are studying whether daily aspirin can help prevent preeclampsia and improve pregnancy outcomes in women who are pregnant for the first time after assisted reproductive technology. This trial compares aspirin to a placebo to see which is more effective.

Preeclampsia>2 yearsConfirmation phase (III)Monitoring phase (IV)≤5 visitsStandard MedicinesPartially RemoteGynecology and Obstetrics

Acute Venous Thromboembolism: Anticoagulant Therapy Study

We are studying whether full-dose anticoagulant therapy alone is safer and more effective than combining it with antiplatelet therapy for patients with acute VTE. This research aims to improve treatment options for those already taking antiplatelets.

Deep Venous Thrombosis and Pulmonary Embolism>2 yearsConfirmation phase (III)No PlaceboInvestigational MedicinesCardiologyInternal Medicine

Early Breast Cancer: Imlunestrant vs Standard Therapy

We are studying a new treatment called imlunestrant for patients with early breast cancer who have already received 2 to 5 years of standard therapy. The goal is to see if it helps reduce the risk of cancer returning compared to current treatments.

Breast Cancer>2 yearsConfirmation phase (III)16-20 visitsNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncology

Early Breast Cancer: Camizestrant vs. Standard Therapy

We are studying whether the new medication camizestrant can better prevent breast cancer recurrence in patients who have completed initial treatment. This trial involves individuals with ER+/HER2- early breast cancer at risk of returning after standard therapy.

ER+/HER2- Early Breast Cancer>2 yearsConfirmation phase (III)6-10 visitsNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncology

COPD: Eosinophil-Guided Inhaled Corticosteroid Reduction

We are studying whether adjusting inhaled corticosteroid treatment based on eosinophil levels helps patients with severe COPD. We also want to see if low-dose Azithromycin can reduce hospital visits and improve overall health.

Chronic Obstructive Pulmonary Disease (COPD)>2 yearsMonitoring phase (IV)Standard MedicinesInternal MedicinePulmonology

Acute Lymphoblastic Leukaemia: ALLTogether Treatment Study

We are studying new treatment options for children and young adults aged 0-45 with newly diagnosed acute lymphoblastic leukaemia. The goal is to improve survival and quality of life through various interventions.

Acute Lymphoblastic Leukaemia>2 yearsEfficacy phase (II)Confirmation phase (III)No PlaceboStandard MedicinesHematologyOncology

ANCA-Associated Vasculitis: Pioglitazone Treatment

We are studying whether adding pioglitazone to standard treatments can improve kidney function in patients with ANCA-associated vasculitis. The trial also looks at quality of life and potential side effects.

ANCA-associated Vasculitis>2 yearsConfirmation phase (III)11-15 visitsStandard MedicinesPartially RemoteNephrologyRheumatology

Semaglutide for Acute Ischemic Stroke

We are studying whether a new injection of semaglutide is safe and effective for non-diabetic patients right after an ischemic stroke. This trial aims to improve treatment options during this critical time.

Ischemic Stroke≤3 monthsEfficacy phase (II)No PlaceboInvestigational MedicinesCardiologyNeurology

Biliary Atresia: Long-term Study of Odevixibat

We are studying the long-term effects of odevixibat in children with biliary atresia to see if it helps improve liver health and overall growth. The trial also looks at the safety of this treatment over time.

Biliary Atresia>2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteHepatologyPediatrics

Infantile-onset Pompe Disease: Cipaglucosidase Alfa/Miglustat Study

We are evaluating a new treatment for children under 18 with infantile-onset Pompe disease to see if it is safe and effective. This study includes both children who have and have not received previous enzyme replacement therapy.

Pompe's Disease (Infantile Onset)>2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteHematologyInternal MedicineNeurologyPediatrics

Migraine Prevention: Atogepant for Kids

We are studying the long-term safety and tolerability of atogepant in children and teens aged 6 to 17 with migraines. This research aims to ensure the treatment is safe for young patients.

Migraine1-2 yearsConfirmation phase (III)11-15 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteNeurologyPediatrics

Episodic Migraine: Atogepant for Kids and Teens

We are studying the safety and effectiveness of Atogepant tablets for children and teens aged 6 to 17 with episodic migraines. This trial compares the medication to a placebo to see if it helps reduce migraine symptoms.

Episodic Migraine3-6 monthsConfirmation phase (III)6-10 visitsStandard MedicinesCost ReimbursementPartially RemoteNeurologyPediatrics

Ulcerative Colitis: GS-5290 Medication Study

We are testing a new medication for people with moderately to severely active ulcerative colitis to see if it helps improve symptoms better than a placebo. The study will assess various measures of clinical response and remission.

Ulcerative Colitis1-2 yearsEfficacy phase (II)11-15 visitsInvestigational MedicinesCost ReimbursementGastroenterologyInternal Medicine

Arthritis from Cancer Immunotherapy: Tocilizumab Study

We are investigating whether adding tocilizumab to short-term glucocorticoids helps people with arthritis caused by cancer immunotherapy more than glucocorticoids alone. This study aims to improve arthritis control and patient outcomes.

Arthritis from Cancer TreatmentEfficacy phase (II)No PlaceboStandard MedicinesOncologyRheumatology

Primary Membranous Nephropathy: Zanubrutinib vs. Tacrolimus

We are studying whether zanubrutinib can reduce protein levels in urine and lead to remission in patients with primary membranous nephropathy compared to tacrolimus. This trial aims to evaluate the safety and effectiveness of both treatments.

Primary Membranous Nephropathy1-2 yearsEfficacy phase (II)Confirmation phase (III)11-15 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteNephrology

HER2-Positive Early Breast Cancer: Inavolisib Study

We are investigating whether adding the drug inavolisib to standard treatments helps patients with HER2-positive, HR-positive, PIK3CA mutant early breast cancer achieve better treatment responses. This study compares the new combination therapy to standard therapy alone.

Breast Cancer3-6 monthsEfficacy phase (II)No PlaceboInvestigational MedicinesOncology

Stroke Prevention: Milvexian Study

We are testing a new oral medication, milvexian, for individuals who have had an acute ischemic stroke or high-risk transient ischemic attack. The study aims to see if it can lower the risk of future strokes and other heart-related issues.

Acute Ischemic Stroke and High-Risk Transient Ischemic Attack>2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteCardiologyInternal Medicine